Big pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billion

As Novo Nordisk and Eli Lilly duke it out in the weight-loss drug market with Ozempic, Wegovy and Mounjaro, drug company competitors plan to join the fray.